Axa’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.05M | Buy |
16,705
+1,668
| +11% | +$133K | 0.41% | 41 |
|
|
2025
Q4 | $1.43M | Sell |
15,037
-2,588
| -15% | -$254K | 0.68% | 32 |
|
|
2025
Q3 | $1.72M | Sell |
17,625
-2,494,302
| -99% | -$258M | 0.86% | 22 |
|
|
2025
Q2 | $270M | Buy |
2,511,927
+317,311
| +14% | +$32.1M | 0.78% | 20 |
|
|
2025
Q1 | $221M | Buy |
2,194,616
+221,871
| +11% | +$22.3M | 0.73% | 24 |
|
|
2024
Q4 | $176M | Buy |
1,972,745
+9,597
| +0.5% | +$845K | 0.54% | 35 |
|
|
2024
Q3 | $165M | Sell |
1,963,148
-53,582
| -3% | -$4.22M | 0.49% | 35 |
|
|
2024
Q2 | $155M | Sell |
2,016,730
-302,661
| -13% | -$22.2M | 0.46% | 39 |
|
|
2024
Q1 | $159M | Sell |
2,319,391
-138,698
| -6% | -$8.92M | 0.48% | 41 |
|
|
2023
Q4 | $142M | Sell |
2,458,089
-160,177
| -6% | -$8.55M | 0.46% | 45 |
|
|
2023
Q3 | $138M | Sell |
2,618,266
-147,856
| -5% | -$7.75M | 0.49% | 41 |
|
|
2023
Q2 | $150M | Buy |
2,766,122
+544,921
| +25% | +$28.5M | 0.5% | 38 |
|
|
2023
Q1 | $111M | Sell |
2,221,201
-6,417
| -0.3% | -$302K | 0.38% | 62 |
|
|
2022
Q4 | $103M | Buy |
2,227,618
+214,878
| +11% | +$9.3M | 0.37% | 58 |
|
|
2022
Q3 | $78M | Sell |
2,012,740
-82,188
| -4% | -$3.3M | 0.31% | 80 |
|
|
2022
Q2 | $78.1M | Buy |
2,094,928
+45,761
| +2% | +$1.86M | 0.29% | 81 |
|
|
2022
Q1 | $90.8M | Buy |
2,049,167
+306,950
| +18% | +$13.3M | 0.26% | 96 |
|
|
2021
Q4 | $74M | Sell |
1,742,217
-15,649
| -0.9% | -$658K | 0.19% | 129 |
|
|
2021
Q3 | $76.3M | Buy |
1,757,866
+242,976
| +16% | +$10.7M | 0.21% | 116 |
|
|
2021
Q2 | $64.8M | Sell |
1,514,890
-86,812
| -5% | -$3.65M | 0.18% | 137 |
|
|
2021
Q1 | $61.9M | Buy |
1,601,702
+339,425
| +27% | +$12.8M | 0.19% | 130 |
|
|
2020
Q4 | $45.4M | Buy |
1,262,277
+138,333
| +12% | +$4.99M | 0.14% | 170 |
|
|
2020
Q3 | $42.9M | Buy |
1,123,944
+140,918
| +14% | +$5.43M | 0.16% | 152 |
|
|
2020
Q2 | $34.5M | Sell |
983,026
-185,568
| -16% | -$6.68M | 0.14% | 177 |
|
|
2020
Q1 | $38.1M | Buy |
1,168,594
+144,678
| +14% | +$5.65M | 0.19% | 130 |
|
|
2019
Q4 | $46.3M | Buy |
1,023,916
+12,321
| +1% | +$516K | 0.19% | 132 |
|
|
2019
Q3 | $41.2M | Buy |
1,011,595
+92,328
| +10% | +$3.91M | 0.16% | 164 |
|
|
2019
Q2 | $39.5M | Buy |
919,267
+69,320
| +8% | +$2.67M | 0.15% | 183 |
|
|
2019
Q1 | $32.6M | Sell |
849,947
-2,914
| -0.3% | -$111K | 0.13% | 207 |
|
|
2018
Q4 | $30.1M | Sell |
852,861
-174,273
| -17% | -$6.32M | 0.13% | 209 |
|
|
2018
Q3 | $39.5M | Sell |
1,027,134
-61,035
| -6% | -$2.13M | 0.15% | 188 |
|
|
2018
Q2 | $35.6M | Sell |
1,088,169
-123,938
| -10% | -$3.74M | 0.14% | 201 |
|
|
2018
Q1 | $33.1M | Sell |
1,212,107
-37,680
| -3% | -$1.02M | 0.13% | 195 |
|
|
2017
Q4 | $31M | Buy |
1,249,787
+17,475
| +1% | +$482K | 0.12% | 219 |
|
|
2017
Q3 | $35.9M | Sell |
1,232,312
-130,067
| -10% | -$3.59M | 0.15% | 189 |
|
|
2017
Q2 | $37.8M | Sell |
1,362,379
-213,542
| -14% | -$5.67M | 0.17% | 171 |
|
|
2017
Q1 | $39.2M | Buy |
1,575,921
+599,019
| +61% | +$14.6M | 0.18% | 169 |
|
|
2016
Q4 | $21.1M | Sell |
976,902
-146,838
| -13% | -$3.2M | 0.1% | 246 |
|
|
2016
Q3 | $26.7M | Buy |
1,123,740
+183,200
| +19% | +$4.37M | 0.12% | 220 |
|
|
2016
Q2 | $22M | Buy |
940,540
+35,200
| +4% | +$762K | 0.1% | 254 |
|
|
2016
Q1 | $17M | Sell |
905,340
-4,855
| -0.5% | -$85.3K | 0.08% | 282 |
|
|
2015
Q4 | $16.8M | Buy |
910,195
+902,595
| +11,876% | +$16.2M | 0.07% | 270 |
|
|
2015
Q3 | $125K | Hold |
7,600
| – | – | ﹤0.01% | 1266 |
|
|
2015
Q2 | $135K | Sell |
7,600
-100
| -1% | -$1.79K | ﹤0.01% | 1259 |
|
|
2015
Q1 | $137K | Sell |
7,700
-7,920,960
| -100% | -$125M | ﹤0.01% | 1278 |
|
|
2014
Q4 | $105M | Buy |
7,928,660
+1,096,700
| +16% | +$14M | 0.42% | 58 |
|
|
2014
Q3 | $80.7M | Buy |
6,831,960
+2,437,710
| +55% | +$30.7M | 0.34% | 72 |
|
|
2014
Q2 | $56.1M | Buy |
+4,394,250
| New | +$57.1M | 0.23% | 126 |
|
Other funds holding BSX
VCM
VPM
Axa's BSX Position: Q1 2026 in Review
Axa increased its Boston Scientific (BSX) stake by 11% in Q1 2026, buying an estimated $133K and bringing the position to 16,705 shares worth $1.05M. The position accounts for 0.41% of the portfolio, ranked #41.
Axa first reported a position in BSX in Q2 2014 and has held it in 48 quarters since. The position peaked at $270M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Axa held 16,705 shares of Boston Scientific worth $1.05M as of Q1 2026.
- Axa bought 1,668 Boston Scientific shares in Q1 2026, an estimated $133K.
- Boston Scientific made up 0.41% of Axa's portfolio in Q1 2026, its #41 holding.
- Axa first reported a position in Boston Scientific in Q2 2014 and has held it in 48 quarters since.
- Axa's Boston Scientific position peaked at $270M in Q2 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Axa's 13F filing for Q1 2026, filed 15 May 2026.